The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma
2 Tampilan
• 07/18/23
0
0
Menanamkan
administrator
Pelanggan
Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.
Menampilkan lebih banyak
Komentar Facebook
SORT BY-
Komentar Teratas
-
komentar terbaru